FDA Grants Breakthrough Device Designation for Biological Dynamics’ Early-stage Pancreatic Cancer Detection Test

/

Biological Dynamics, Inc., a multiomics liquid biopsy company focused on detecting cancers at the earliest stages, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its liquid biopsy assay, Exo-PDAC. The test is designed to provide early detection for pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and lethal forms of cancer worldwide.

Read More

Biological Dynamics to Present at UBS Genomics 2.0 and MedTech Innovations Summit

/

Biological Dynamics, Inc., a next-generation liquid biopsy company focused on detecting cancers at the earliest stages, will present at the UBS Genomics 2.0 and MedTech Innovations Summit in Laguna Beach, California. The panel discussion takes place on Tuesday, August 10, 2021 at 7:00 p.m. PT.

Kevin Han, CFO, will be joined by Dr. Dave Hoon, Professor and Director, Translational Molecular Medicine and Genome Sequencing at Saint John's Cancer Institute to collaborate in a panel discussion, Emerging Players in Liquid Biopsy, focused on Biological Dynamics’ patented technology that empowers cancer detection at the earliest stages.

Read More

Biological Dynamics to Participate in the Nephron Research Liquid Biopsy Innovation Symposium

/

CEO Raj Krishnan, Ph.D. and CFO Kevin Han, will be joined by Dr. Dave Hoon, Professor and Director, Translational Molecular Medicine and Genome Sequencing at Saint John's Cancer Institute to collaborate in a panel discussion, Novel Approaches for Early Cancer Detection, on Wednesday, June 16, 2021, at 12:10 p.m. ET / 9:10 a.m. PT.

Biological Dynamics will discuss a transformative approach to cancer screening using a proprietary platform that enables the isolation and evaluation of non-DNA biomarkers, such as exosomes, exo-proteins, and surfaceomes. The company will also discuss how the access to these differentiated biomarkers from blood can empower cancer detection at the earliest stages.

Read More

Biological Dynamics to Present at the 39th Annual J.P. Morgan Healthcare Conference

/

Biological Dynamics, Inc., a healthcare company committed to improving global health outcomes by detecting diseases at an early stage, will present at the 39th Annual J.P. Morgan Healthcare Conference. CEO Raj Krishnan, Ph.D. and CFO Kevin Han, will provide an overview of the company and host a Q&A on Tuesday, January 12, 2021, at 5:30 p.m. ET.

Read More